COSMOS HEALTH, INC.

BGSF: Click to Subscribe to Email Notifications

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC Filings

Report Link: Initial Research Report (Dated February 20, 2024)

Symbol: COSM
Analyst: Howard Halpern
Taglich Rating: Speculative Buy
Price Target: $4.00
Time Horizon: 12 Months
Rating Established: February 20, 2024
Price When Established: $0.83
Most Recent Report: February 20, 2024
Price When Issued: $0.83

What’s New

Cosmos Health Acquired the PELOFARM I.K.E Pharmacy Distribution Network

On June 13, 2024, Cosmos Health announced it acquired the pharmacy distribution network owned by PELOFARM Ι.Κ.Ε., a pharmaceutical wholesale company operating in the region of Arcadia, Greece, since 1985.

This bolt-on transaction, through the company’s CosmoFarm Pharmaceuticals subsidiary, entails the acquisition of Pelofarm’s sales and distribution network, which serves more than 30 pharmacies in Arcadia and surrounding areas in the central Peloponnese. Additionally, CosmoFarm is well-positioned to expand its reach to at least 20 more pharmacies in the region.

While terms of the deal were not disclosed, it is anticipated this acquisition could contribute at least $5 million annually to COSM’s revenues.

Cosmos Health Receives Regulatory Approvals in United Arab Emirates

On March 18, 2024, Cosmos Health announced it received regulatory approval to sell its Sky Premium Life® vitamins and food supplements in the United Arab Emirates

While initial purchase orders were obtained, the company is in advanced discussions with leading local entities and anticipates securing an exclusive distribution agreement.

Entering this market occurred as COSM obtained Consumer Product Registration Certificates from the Public Health and Safety Department of the Government of Dubai. Registration Certificates are valid for five years are renewable and allow the free distribution of products in the UAE market.

Company Description

Cosmos Health Inc., headquartered in Chicago, Illinois is a diversified vertically integrated global health organization that manufactures and distributes medical grade nutritional and medicines. Cosmos owns a portfolio of proprietary pharmaceutical and nutraceutical brands (Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®). Its CANA Pharmaceuticals Laboratories subsidiary is licensed to manufacture pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. COSM also distributes a broad line of pharmaceuticals and parapharmaceuticals that includes branded, generics, and OTC medications to retail pharmacies and wholesale distributors in Greece and the United Kingdom. Through a repurposing drug program, COSM is targeting major health disorders such as obesity, diabetes, and cancer.

Disclaimer
Please view our current disclosure and disclaimer on our most recent research report.